Clinical Trial Safety Reporting: Are You Compliant with Current FDA Requirements?
Date: –
Duration: 60 Minutes
Time: 12 PM EST
Clinical trial safety reporting has changed significantly since many organizations established their current processes. FDA’s December 2025 final guidance on Sponsor Responsibilities for Safety Reporting and Safety Assessment and its companion guidance on Investigator Responsibilities for Safety Reporting provide updated recommendations for sponsors, sponsor-investigators and clinical investigators.
At the same time, ClinicalTrials.gov continues to impose detailed requirements for reporting adverse-event results, while the evolving GCP framework places greater emphasis on risk-based oversight, data quality and systematic safety assessment. This updated webinar brings these developments together to help clinical research professionals evaluate whether their current safety-reporting practices remain aligned with today’s expectations.
Why This Webinar Matters Now
A serious adverse event does not automatically mean an expedited IND safety report is required. Sponsors must evaluate seriousness, unexpectedness, suspected causality and other relevant evidence before determining whether expedited reporting is warranted.
FDA’s updated guidance also places greater emphasis on aggregate safety assessment, systematic surveillance and evaluation of accumulating data rather than relying exclusively on individual case reports. For organizations still relying primarily on legacy safety-reporting procedures, this is an important opportunity to reassess their processes.
What You Will Learn
1. Understand the Current FDA Safety-Reporting Framework
Gain a practical understanding of the current FDA requirements under 21 CFR 312.32 and related provisions, including:
- Adverse events vs. serious adverse events
- Suspected adverse reactions
- Unexpectedness and causality
- Criteria for expedited IND safety reporting
- Significant increases in the occurrence of serious suspected adverse reactions
- Other findings that may indicate significant human risk
The program will explain how these concepts work together when determining whether a safety report should be submitted to FDA.
2. Know When a Serious Adverse Event Requires Expedited Reporting
One of the most important compliance questions is: Does every serious adverse event need to be reported to FDA as an expedited IND safety report? Participants will examine practical scenarios and learn how sponsors should evaluate individual cases, medical significance, expectedness, causality and available evidence before making a reporting decision.
3. Move Beyond Individual Case Reports
Modern safety surveillance requires more than reviewing individual cases. The webinar explores FDA expectations around:
- Aggregate safety analysis
- Cross-study and pooled data evaluation
- Comparison with control groups
- Emerging safety signals
- Systematic safety surveillance
- Safety assessment plans
- Follow-up evaluation of potential signals
FDA’s current sponsor guidance specifically addresses the use of aggregate data in determining whether reporting obligations have been triggered.
4. Clarify Sponsor, Investigator and IRB Responsibilities
Safety-reporting failures can occur when responsibilities are misunderstood or duplicated. This session clarifies what information should flow between investigators, sponsors, sponsor-investigators and IRBs, including the investigator’s responsibility to identify and communicate relevant safety information and the sponsor’s role in evaluating information for regulatory reporting. FDA’s December 2025 investigator guidance specifically addresses safety information that investigators should report to sponsors and IRBs.
5. Connect FDA Safety Reporting With ClinicalTrials.gov
FDA reporting and ClinicalTrials.gov reporting are related—but they are not the same process. Participants will review ClinicalTrials.gov requirements for:
- All-cause mortality
- Serious adverse events
- Other adverse events
- Participants affected and participants at risk
- Frequency thresholds
- Systematic vs. non-systematic assessment
- Standardized terminology and source vocabularies
- Adverse-event reporting descriptions
ClinicalTrials.gov requires structured adverse-event information by study arm or comparison group, with specific requirements for serious and other adverse events.
6. Apply a Risk-Based Approach to Safety Oversight
The modern clinical-trial environment increasingly emphasizes risk-based quality management, quality by design, data integrity and proactive identification of critical safety issues.Participants will explore how these principles can be incorporated into clinical-trial safety surveillance rather than treating safety reporting as a purely reactive compliance function.
7. Prepare for Modern Electronic Safety Reporting
The webinar also addresses the evolution of electronic safety reporting, including E2B(R3), FDA’s Adverse Event Monitoring System (AEMS), electronic submission expectations and operational readiness. This is particularly relevant for organizations updating their safety-reporting infrastructure and procedures.
Key Takeaway
The goal is not simply to understand what to report to FDA. It is to understand how to build a safety-reporting process that is accurate, timely, risk-based, evidence-driven and inspection-ready. By the end of this webinar, participants will be better positioned to evaluate their current processes, identify potential compliance gaps and establish a more integrated approach to clinical-trial safety reporting—from individual adverse-event assessment through aggregate safety analysis, FDA reporting and ClinicalTrials.gov results disclosure.
Who Should Attend?
This webinar is particularly relevant for professionals involved in clinical-trial safety, regulatory compliance and clinical data oversight, including:- Clinical Research
- Pharmacovigilance
- Drug Safety
- Regulatory Affairs
- Medical Affairs
- Clinical Data Management
- Clinical Operations
- Quality Assurance
- Compliance | Biostatistics
- Medical Monitors
- Investigators
- Sponsor Organizations
- CROs
Speaker: Mukesh Kumar
PhD, RAC | CEO, FDAMap
For more info, fill the box below. We will contact you within 24 hrs.
Webinar Fee
Prices are in US Dollars.
The registration fee includes: The live webinar & all related course materials.
Terms & Conditions to register for the Webinar
Your Registration for the workshop is subject to following terms and conditions. If you need any clarification before registering for this webinar please email us at info@fdamap.com
Payment
We accept credit card, debit card, and PayPal.
Cancellations & Substitutions:
Written cancellations through fax or email (from the person who has registered for this conference) received at least 5 business days prior to the start date of the event will receive a refund — less a $30 administration fee. No cancellations will be accepted — nor refunds issued — within 5 business days before the start date of the event. You may however, choose to substitute the webinar for which you are registered with some other webinar in the future.
On request by email or fax (before the seminar) a credit for the amount paid minus administration fees ($30) will be transferred to any future FDA Map event and a credit note will be issued. No-shows will be charged the full amount.
Webinar material will be uploaded on the website 24 hours before the scheduled date of the webinar. In case it is not available on the website due to some technical issues, we will email the material a few hours before the start of the webinar.
In the event FDA Map cancels the webinar, FDA Map will issue a full refund to all the registrants for that webinar. Some topics and speakers may be subject to change without notice.
